Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies

2014 ◽  
Vol 3 (2) ◽  
pp. 175-190 ◽  
Author(s):  
Lu-Lu Yang ◽  
Yi-Long Wu
Keyword(s):  
Lung Cancer ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Programmed Death Ligand 1 ◽  
Recent Advances ◽  
Programmed Death ◽  
Programmed Cell Death 1

scholarly journals The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy

2019 ◽  
Vol 19 (4) ◽  
pp. 277 ◽  
Author(s):  
Malika Al-Dughaishi ◽  
Asem Shalaby ◽  
Khawla Al-Ribkhi ◽  
Ammar Boudaka ◽  
Mohamed-Rachid Boulassel ◽  
...  
Keyword(s):  
Cell Death ◽  
Neoadjuvant Chemotherapy ◽  
Programmed Cell Death ◽  
Cancer Patients ◽  
Cell Activity ◽  
Programmed Death Ligand 1 ◽  
Tumour Immunity ◽  
Programmed Death ◽  
Programmed Cell Death 1

Programmed death ligand 1 (PD-L1) is an inhibitory molecule expressed by cancer cells to supress T-cell activity and escape anti-tumour immunity. The role of PD-L1 in cancer has been studied extensively as it is considered an important immune checkpoint against immune over-activation through its interaction with Programmed death receptor 1 (PD-1) expressed on activated lymphocytes. PD-L1 expression was found to be enhanced by chemotherapy through different proliferation pathways. However, the predictive and prognostic value for PD-L1 expression in cancer patients treated with neoadjuvant chemotherapy (NAC) is not yet established. This review focused on the potential effects of chemotherapy on PD-L1 expression and the role of PD-L1 as a prognostic and predictive marker in NAC-treated cancer patients. In addition, the potential use of this marker in clinical practice is discussed.Keywords: Programmed Cell Death 1 Ligand 1; Programmed Cell Death 1 Receptor; Neoadjuvant Therapy; Cancer.

Sign in / Sign up

Export Citation Format

Share Document